---
title: "Shanghai Bao Pharma Wins NMPA Nod for Recombinant Human Hyaluronidase Injection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281971171.md"
description: "Shanghai Bao Pharmaceuticals has received approval from China's National Medical Products Administration for its Human Hyaluronidase for Injection (KJ017). This product, designed to enhance subcutaneous infusion of solutions, offers a safer alternative to traditional animal-derived hyaluronidase by reducing immunogenicity risk and improving consistency. The approval strengthens the company's position in advanced injectable delivery technologies, targeting patients with difficult intravenous access. Shanghai Bao Pharmaceuticals is a Hong Kong-listed drug manufacturer focused on innovative injectable therapies."
datetime: "2026-04-08T04:10:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281971171.md)
  - [en](https://longbridge.com/en/news/281971171.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281971171.md)
---

# Shanghai Bao Pharma Wins NMPA Nod for Recombinant Human Hyaluronidase Injection

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Shanghai Bao Pharmaceuticals Co Ltd Class H ( (HK:2659) ) has shared an update.

Shanghai Bao Pharmaceuticals announced that its internally developed Human Hyaluronidase for Injection, under project code KJ017, has been approved for marketing by China’s National Medical Products Administration. The 385U/vial formulation is cleared as an adjuvant to subcutaneous infusion of solutions such as sodium chloride injection and sodium lactate Ringer’s injection, enabling large-volume subcutaneous administration.

KJ017 is a highly glycosylated recombinant human hyaluronidase that temporarily increases subcutaneous tissue permeability, offering a safer and more convenient alternative to traditional animal-derived hyaluronidase. By reducing immunogenicity risk, eliminating the need for pre-use skin testing, and improving batch consistency, the product could enhance clinical practice for difficult intravenous access patients and strengthen the company’s position in advanced injectable delivery technologies.

**More about Shanghai Bao Pharmaceuticals Co Ltd Class H**

Shanghai Bao Pharmaceuticals Co., Ltd. is a China-based drug manufacturer listed in Hong Kong that focuses on developing innovative injectable therapies. The company targets hospital and clinical settings with products designed to improve drug delivery, particularly for patients who face challenges with conventional intravenous administration routes.

**Average Trading Volume:** 683,814

**Current Market Cap:** HK$15.86B

For an in-depth examination of 2659 stock, go to TipRanks’ Overview page.

### Related Stocks

- [02659.HK](https://longbridge.com/en/quote/02659.HK.md)

## Related News & Research

- [16:44 ET/C O R R E C T I O N -- Skyhawk Therapeutics/](https://longbridge.com/en/news/286817312.md)
- [12:46 ETEyePromise Introduces Heyedrate™ Clinical: A Next Generation Artificial Tear](https://longbridge.com/en/news/286800296.md)
- [Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus | OTLC Stock News](https://longbridge.com/en/news/286276734.md)
- [11:48 ETInventHelp Inventor Develops New Remote Control Finder (TKA-458)](https://longbridge.com/en/news/286941635.md)
- [12:45 ETInventHelp Inventor Develops New Bandage Dispenser (TLS-1305)](https://longbridge.com/en/news/286946419.md)